
## Sheldon S Leung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/599730/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mapping contacts between gRNA and mRNA in trypanosome RNA editing. Nucleic Acids Research, 1999, 27, 778-787.	14.5	46
2	One Mouse, One Pharmacokinetic Profile: Quantitative Whole Blood Serial Sampling for Biotherapeutics. Pharmaceutical Research, 2014, 31, 1823-1833.	3.5	45
3	Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD. Bioanalysis, 2012, 4, 2589-2604.	1.5	34
4	Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles. Science Advances, 2021, 7, .	10.3	28
5	Protein-based matrix interferences in ligand-binding assays. Bioanalysis, 2014, 6, 1131-1140.	1.5	25
6	Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia. Nature Communications, 2022, 13, 272.	12.8	24
7	Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. MAbs, 2016, 8, 848-853.	5.2	23
8	Use of response surface methods and path of steepest ascent to optimize ligand-binding assay sensitivity. Journal of Immunological Methods, 2013, 392, 12-23.	1.4	20
9	ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia. Molecular Therapy - Methods and Clinical Development, 2021, 22, 279-292.	4.1	17
10	lkirara Insertions Reveal Five New Anopheles gambiae Transposable Elements in Islands of Repetitious Sequence. Journal of Molecular Evolution, 2001, 52, 215-231.	1.8	15
11	Pharmacokinetics of anti-IL17A and anti-IL22 peptide–antibody bispecific genetic fusions in mice. International Immunopharmacology, 2014, 18, 225-227.	3.8	12
12	Ligand-Binding Assays in the 21st Century Laboratory: Recommendations for an Automated Data Interchange Process. AAPS Journal, 2012, 14, 105-112.	4.4	6
13	Discovery fit-for-purpose ligand-binding PK assays: what's really important?. Bioanalysis, 2013, 5, 1463-1466.	1.5	5
14	Automate it: ligand-binding assay productivity in a discovery bioanalytical setting. Bioanalysis, 2013, 5, 1775-1782.	1.5	2
15	Getting from proto-sharing to sharing: collaborating on electronic solutions for ligand-binding assays. Bioanalysis, 2011, 3, 1411-1413.	1.5	0